Assessing Islet Transplantation Outcome in Mice

  • Aileen J. F. KingEmail author
  • Chloe L. Rackham
Part of the Methods in Molecular Biology book series (MIMB, volume 2076)


Islet transplantation is a potential treatment for Type 1 diabetes; however, improvements need to be made before it could become clinically widely available. In preclinical studies, the mouse is often used to model islet transplantation, with most studies aiming to improve transplantation outcome by manipulating the islets prior to transplantation or by treating the recipient mouse. Here, we describe the process of islet transplantation in the mouse, including how one can make the mouse diabetic, isolate donor islets, and transplant the islets into two different sites. Finally, we discuss how to assess the outcome of the transplantation in order to determine whether the experimental intervention has been beneficial.

Key words

Islet transplantation Mouse Islet isolation Intraportal islet transplantation Renal subcapsular islet transplantation 


  1. 1.
    Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ (2014) Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes, Metab Syndr Obes 7:211–223Google Scholar
  2. 2.
    Zhi ZL, Kerby A, King AJ, Jones PM, Pickup JC (2012) Nano-scale encapsulation enhances allograft survival and function of islets transplanted in a mouse model of diabetes. Diabetologia 55:1081–1090CrossRefGoogle Scholar
  3. 3.
    Kerby A, Bohman S, Westberg H, Jones P, King A (2012) Immunoisolation of islets in high guluronic acid barium-alginate microcapsules does not improve graft outcome at the subcutaneous site. Artif Organs 36:564–570CrossRefGoogle Scholar
  4. 4.
    Estil les E, Tellez N, Escoriza J, Montanya E (2012) Increased beta-cell replication and beta-cell mass regeneration in syngeneically transplanted rat islets overexpressing insulin-like growth factor II. Cell Transplant 21:2119–2129CrossRefGoogle Scholar
  5. 5.
    Fernandes JR, Duvivier-Kali VF, Keegan M et al (2004) Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol 13:191–200CrossRefGoogle Scholar
  6. 6.
    King A, Lock J, Xu G, Bonner-Weir S, Weir GC (2005) Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 48:2074–2079CrossRefGoogle Scholar
  7. 7.
    McCall M, Toso C, Emamaullee J et al (2011) The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 150:48–55CrossRefGoogle Scholar
  8. 8.
    King AJ, Guo Y, Cai D et al (2013) Sustained NF-kappaB activation and inhibition in beta-cells have minimal effects on function and islet transplant outcomes. PLoS One 8:e77452CrossRefPubMedGoogle Scholar
  9. 9.
    Toso C, Serre-Beinier V, Emamaullee J et al (2008) The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 86:1361–1369CrossRefGoogle Scholar
  10. 10.
    Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ (2011) Co-transplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 54:1127–1135CrossRefGoogle Scholar
  11. 11.
    Pawlick R, Gala-Lopez B, Pepper AR, McCall M, Ziff O, Shapiro AM (2014) The combination of anti-NKG2D and CTLA-4 Ig therapy prolongs islet allograft survival in a murine model. Am J Transplant 14:2367–2374CrossRefGoogle Scholar
  12. 12.
    Bohman S, Andersson A, King A (2006) No differences in efficacy between noncultured and cultured islets in reducing hyperglycemia in a nonvascularized islet graft model. Diabetes Technol Ther 8:536–545CrossRefGoogle Scholar
  13. 13.
    Deeds MC, Anderson JM, Armstrong AS et al (2011) Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim 45:131–140CrossRefPubMedGoogle Scholar
  14. 14.
    King A, Bowe J (2016) Animal models for diabetes: understanding the pathogenesis and finding new treatments. Biochem Pharmacol 99:1–10CrossRefGoogle Scholar
  15. 15.
    King AJ, Austin AL, Nandi M, Bowe JE (2016) Diabetes in rats is cured by islet transplantation... but only during daytime. Cell Transplant 26(1):171–172CrossRefGoogle Scholar
  16. 16.
    Mathews CE, Langley SH, Leiter EH (2002) New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. Transplantation 73:1333–1336CrossRefGoogle Scholar
  17. 17.
    Hong J, Yeom HJ, Lee E et al (2013) Islet allograft rejection in sensitized mice is refractory to control by combination therapy of immune-modulating agents. Transpl Immunol 28:86–92CrossRefGoogle Scholar
  18. 18.
    Krautz C, Wolk S, Steffen A et al (2013) Effects of immunosuppression on alpha and beta cell renewal in transplanted mouse islets. Diabetologia 56:1596–1604CrossRefGoogle Scholar
  19. 19.
    Chen X, Zhang X, Chen F, Larson CS, Wang LJ, Kaufman DB (2009) Comparative study of regenerative potential of beta cells from young and aged donor mice using a novel islet transplantation model. Transplantation 88:496–503CrossRefGoogle Scholar
  20. 20.
    Leiter EH, Schile A (2013) Genetic and pharmacologic models for type 1 diabetes. Curr Protoc Mouse Biol 3:9–19CrossRefPubMedGoogle Scholar
  21. 21.
    Sakata N, Yoshimatsu G, Tsuchiya H, Egawa S, Unno M (2012) Animal models of diabetes mellitus for islet transplantation. Exp Diabetes Res 2012:256707CrossRefPubMedGoogle Scholar
  22. 22.
    McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH (2009) NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Phys Endocrinol Metab 297:E849–E855CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Diabetes Research Group, School of Life Course SciencesKing’s College LondonLondonUK

Personalised recommendations